Full Press Release Details
Intelligent Bio Solutions Inc. Announces Proposed
Public Offering of Common Stock
NEW YORK, February 19, 2025
- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the "Company") a medical technology company delivering intelligent,
rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock.
All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and
there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Ladenburg Thalmann &
Co. Inc. is acting as the sole bookrunning manager for the offering.
The offering is being made
pursuant to a shelf registration statement filed with the Securities and Exchange Commission ("SEC") on April 8, 2022, and
declared effective by the SEC on April 20, 2022.
A preliminary prospectus
supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website
at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering, when available,
may also be obtained by contacting Ladenburg Thalmann & Co. Inc. at Attn: Prospectus Department, 640 Fifth Avenue, 4th Floor, New
York, NY 10019 or by e-mail at prospectus@ladenburg.com.
This press release shall
not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in
any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction.
About Intelligent Bio
Intelligent Bio Solutions
Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes
that its Intelligent Fingerprinting Drug Screening System will transform portable testing through fingerprint sweat analysis, which has
the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the
recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection
in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The
Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics
firms, drug treatment organizations, and coroners. For more information, visit: http://www.ibs.inc
Forward-Looking Statements:
Some of the statements in
this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking
statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully consummate
the proposed transaction described in this press release, develop and commercialize its drug and diagnostic tests, realize commercial
benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc.
believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove
to have been materially different from the results expressed or implied by such forward looking statements. Intelligent Bio Solutions
Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates,"
"anticipates," "expects," "plans," "projects," "intends," "potential,"
"may," "could," "might," "will," "should," "approximately" or
other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public
filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of
its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Intelligent Bio Solutions Inc.
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications